Design of rapamycin and resveratrol coloaded liposomal formulation for breast cancer therapy.
Leidiana Rocha Dos ReisMarcela Tavares LuizRafael Miguel SábioGabriel Davi MarenaLeonardo Delello Di FilippoJonatas Lobado DuarteLigia de Souza FernandesVictor Hugo Sousa AraújoViviane Aline Oliveira SilvaMarlus ChorilliPublished in: Nanomedicine (London, England) (2023)
Aims: The development of rapamycin (RAP) and resveratrol (RSV) coloaded liposomes (RAP-RSV-LIP) for breast cancer therapy. Materials & methods: Liposomes were prepared using a high-pressure homogenization technique and evaluated according to their physicochemical characteristics, cellular uptake and cytotoxicity against tumoral and normal cells. Results & conclusion: The RAP-RSV-LIP showed negative surface charge, size around 100 nm, low polydispersity and high encapsulation efficiency for RAP and RSV (58.87 and 63.22%, respectively). RAP-RSV-LIP showed great stability over 60 days and a prolonged drug release profile. In vitro studies indicated that RAP-RSV-LIP were internalized in an estrogen receptor-positive human breast cancer cell line (MCF-7, 34.2%) and improved cytotoxicity when compared with free drugs. Therefore RAP-RSV-LIP showed great antitumoral potential against breast cancer cells.